< The 2016 All-Asia Research Team

Ting (Iris) Wang & team
Credit Suisse
First-place appearances: 1

Total appearances: 7

Team debut: 2008

Ting (Iris) Wang, 33, leads her Asia ex-Japan health care troupe to its third consecutive No. 3 finish. The Credit Suisse researchers — who cover 70 names in this space, working out of Hong Kong, Mumbai and Sydney — win praise from fund managers for providing regular sector updates, making effective stock recommendations and organizing meetings throughout the year. Wang, one admirer notes, “is aggressive on pushing stocks, especially the small caps.” For her part, the 33-year-old crew chief sees promise on the horizon. “The China health care sector has been underperforming the market over the past few months, due to market concerns on potential drug price cuts in the ongoing government-led tenders and prescription volume control by the state health care fund,” she notes. However, “I believe most of the risk in the policy headwinds has been priced in, and the sector will outperform the market in the second half of 2016 if the drug tenders continue to get delayed or the R&D-driven big pharmaceuticals can continue to take market share away from small and uncompetitive ones, thanks to their differentiating product offerings and strong commercialization capabilities.” China Medical System Holdings is her group’s top pick because it boasts one of the most efficient sales teams in the China pharmaceuticals space, the analysts advise, and has built a solid track record in growing underperforming drugs into blockbusters. “In recent years the company has been integrating to the upstream by buying out long-term or permanent commercialization rights in China for high-potential drugs,” Wang says. Their target price for the shares is HK$14.30, implying a 37.2 percent potential upside to their value in late April.